WO2020036135A1 - Particule de type norovirus humain et utilisation associée - Google Patents
Particule de type norovirus humain et utilisation associée Download PDFInfo
- Publication number
- WO2020036135A1 WO2020036135A1 PCT/JP2019/031571 JP2019031571W WO2020036135A1 WO 2020036135 A1 WO2020036135 A1 WO 2020036135A1 JP 2019031571 W JP2019031571 W JP 2019031571W WO 2020036135 A1 WO2020036135 A1 WO 2020036135A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gii
- antibody
- hunov
- protein
- antigen
- Prior art date
Links
- 239000002245 particle Substances 0.000 title description 3
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 208000015181 infectious disease Diseases 0.000 claims abstract description 46
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims abstract description 40
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 39
- 101710197658 Capsid protein VP1 Proteins 0.000 claims abstract description 39
- 101710108545 Viral protein 1 Proteins 0.000 claims abstract description 39
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 230000003053 immunization Effects 0.000 claims abstract description 8
- 241001263478 Norovirus Species 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 description 41
- 238000000034 method Methods 0.000 description 34
- 230000010076 replication Effects 0.000 description 23
- 239000002609 medium Substances 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 210000002220 organoid Anatomy 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- -1 t-butyloxycarbonyl Chemical group 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 101100540835 Mus musculus Wnt3a gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710137396 Protein ORF1 Proteins 0.000 description 1
- 101710132845 Protein P1 Proteins 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710085955 Structural protein 1 Proteins 0.000 description 1
- 101710085959 Structural protein 2 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 102000050526 human RSPO1 Human genes 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to human norovirus-like particles and uses thereof.
- Human norovirus is a pathogenic virus that invades cells of the upper small intestine from the duodenum and causes nonbacterial acute gastroenteritis, and belongs to the non-enveloped Calicivirus family.
- the HuNoV genome is a single-stranded plus-sense RNA of about 7.7 kb.
- a viral protein called VPg is covalently linked to the 5 'end of the genome and the 3' end is polyadenylated.
- ORF1, VP1 and VP2 which code for non-structural protein, structural protein 1 and structural protein 2, respectively.
- HuNoV constructs a truncated icosahedral structure with 90 (by 180 molecules) VP1 dimers.
- Each VP1 monomer is divided into two domains, a shell domain (S domain) and a protruding domain (P domain), of which the P domain is further divided into P1 and P2 subdomains.
- P2 recognizes blood group antigens that function as receptors and host infectious agents during infection. Mutations in the P2 subdomain cause changes in binding to blood group antigens (Non-Patent Document 1).
- HuNoV is classified into three gene groups (GI, GII and GIV) based on the genome sequence, and it is said that there are at least 25 genotypes. Although it is a norovirus that shows high diversity, in recent years, only a small number of strains such as GII, particularly genotype 4 (GII.4) have been responsible for the spread of infection (Non-Patent Document 1). About 20 million HuNoV infections are transmitted annually in the U.S., and about 70,000 are hospitalized. In Japan, there is no clear data, but about 1 to 20,000 inpatients and more than 7 million infections Are estimated to occur every year.
- VLPs virus like particle
- GII.4 is the main genotype in the HuNoV outbreak, but recently other genotypes, especially GII.2, GII.3, GII.6 and GII.17, have become more influential (non-patented).
- References 3-6 Therefore, there is a need for the development of viral therapeutics such as cross-reactive antibodies that inhibit viral infection of several genotypes. However, at present, there is no antibody that inhibits viral infection of multiple genotypes or a single vaccine antigen that can induce it.
- an object of the present invention is to provide an antigen for producing an antibody that suppresses multiple types of HuNoV infection, use thereof, and an antibody that suppresses multiple types of HuNoV infection.
- the present inventors have generated antibodies against GII.4 VLP, GII.3 VLP, and GII.17 VLP, and used a line of intestinal epithelial cells derived from iPS cells (iPSCs) to generate several genes for HuNoV. The type was tested to determine whether it inhibited its infection (HuNoV invasion into and / or replication within intestinal epithelial cells). As a result, an antibody prepared using VLPs formed by self-aggregation of the VP1 protein of GII.4 as an antigen was able to suppress the replication of GII.4, but suppressed the replication of HuNoV of other genotypes. Did not.
- Antibodies prepared using VLPs formed by self-aggregation of the VP1 protein of GII.3 as antigens were able to suppress the replication of GII.3, but inhibited the replication of HuNoV of other genotypes. Did not.
- an antibody prepared using VLPs formed by self-aggregation of the VP1 protein of GII.17 as antigens not only suppresses GII.17 replication but also effectively suppresses GII.4 replication.
- the present invention provides an antigen suitable for the purpose of producing an antibody that inhibits HuNoV infection of a plurality of different genotypes (particularly, GII.4 HuNoV and GII.17 HuNoV), and an antigen produced using the antibody. And the like.
- the present invention includes the following (1) to (10).
- a method for producing an antibody comprising: (2) The method for producing an antibody according to (1) above, wherein the full length of the VP1 protein of GII.17 HuNoV comprises the amino acid sequence represented by SEQ ID NO: 3.
- the antibody or the functional fragment thereof according to the above (4) or (5), wherein the plurality of different genotypes are GII.4 and GII.17.
- a pharmaceutical composition comprising the antibody or the functional fragment thereof according to any of (4) to (6).
- a vaccine for suppressing infection of HuNoV of a plurality of different genotypes which contains the full length or part of GII.17 HuNoV VP1 protein as an antigen.
- the vaccine according to the above (8), wherein the full length of the VP1 protein of GII.17 HuNoV comprises the amino acid sequence represented by SEQ ID NO: 3.
- the vaccine according to (8) or (9), wherein the plurality of different genotypes are GII.4 and GII.17.
- the present invention provides an antigen for producing an antibody that suppresses the replication of HuNoV of a plurality of different genotypes (for example, GII.4 and GII.17).
- the present invention also provides an antibody against the above antigen.
- the antibody can suppress HuNoV infection of a plurality of different genotypes (eg, GII.4 and GII.17), and can provide an effective treatment for HuNoV infection.
- A is the genomic copy number of GII.4 HuNoV (strain 17-231) cultured after pretreatment with anti-GII.4 VLP polyclonal antibody
- B is GII. 3 shows the results of measuring the genome copy number of GII.17 and GII.6 HuNoV. Measurements were taken at 3 hours (open) and 72 hours (black) after infection.
- As a control IgG an unimmunized rabbit-derived IgG was used. Each value is a representative value of three independent experiments and is shown as a mean value ⁇ standard deviation (SD). Effect of anti-GII.3 VLP polyclonal antibody on HuNoV replication.
- A is the genomic copy number of GII.3 HuNoV cultured after pretreatment with an anti-GII.3 VLP polyclonal antibody
- B is GII.4 (17B93 strain), which was pretreated and cultured with an anti-GII.3 VLP polyclonal antibody
- It is the result of measuring the genome copy number of GII.17 and GII.6 HuNoV. Measurements were taken at 3 hours (open) and 72 hours (black) after infection.
- As a control IgG an unimmunized rabbit-derived IgG was used. Each value is a representative value of three independent experiments and is shown as a mean value ⁇ standard deviation (SD). Effect of anti-GII.17 VLP polyclonal antibody on HuNoV replication.
- A shows the genomic copy number of GII.17 HuNoV cultured after pretreatment with anti-GII.17 VLP polyclonal antibody
- B shows GII.4 (strain 17-231) cultured after pretreatment with anti-GII.17 VLP polyclonal antibody. And 17B93 strain), and the results of measuring the genome copy number of GII.3 and GII.6 HuNoV. Measurements were taken at 3 hours (open) and 72 hours (black) after infection.
- As a control IgG an unimmunized rabbit-derived IgG was used. Each value is representative of three independent experiments and is shown as the mean ⁇ SD.
- a first embodiment of the present invention relates to a method for producing an antibody that inhibits infection of a plurality of different genotypes of HuNoV into intestinal epithelial cells, the method comprising: This is a method for producing an antibody, including immunization as an antigen.
- the antibody production method according to the first embodiment shows cross-reactivity with HuNoV of different genotypes and inhibits their infection (or A method for producing an antibody that suppresses the VP1 protein, wherein the full length or a part of the VP1 protein of GII.17 HuNoV is used as an antigen.
- the genotype of HuNoV that the antibody produced by the antibody production method of the present invention inhibits infection is preferably GII.4 or GII.17 belonging to the GII genogroup.
- the VP1 protein of the antigen GII.17 HuNoV may be its full length, or may be a partial region having antigenicity. It is a protein represented by SEQ ID NO: 3.
- the antigenic region can be easily selected by preparing a part of the VP1 protein of GII.17 HuNoV and using it as an immunogen to confirm the neutralizing ability of the antibody (the ability to suppress the replication of HuNoV) can do.
- “GII.17 HuNoV VP1 protein” refers to a protein including the amino acid sequence represented by SEQ ID NO: 3 as well as the amino acid sequence represented by SEQ ID NO: 3 And a protein comprising an amino acid sequence substantially identical to
- the term "protein containing substantially the same amino acid sequence” refers to the amino acid sequence represented by SEQ ID NO: 3 by about 60% or more, preferably about 70% or more, more preferably about 80%, 81%, 82% or more.
- the antibody against the protein comprises an amino acid sequence having about 99% amino acid identity and is capable of infecting intestinal epithelial cells with HuNoVs (eg, GII.4 and GII.17) of multiple different genotypes.
- HuNoVs eg, GII.4 and GII.17
- a protein containing an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 3 refers to one or several (preferably about 1 to 30, more preferably Is composed of an amino acid sequence in which about 1 to 10, more preferably 1 to 5) amino acids have been deleted, substituted, inserted or added, and an antibody against the protein is intestinal tract of HuNoV of a plurality of different genotypes.
- the VP1 protein of GII.17 HuNoV is obtained by obtaining a nucleic acid (for example, SEQ ID NO: 4 or the like) encoding this protein from a cDNA library or the like, incorporating the nucleic acid into an appropriate expression vector, and transforming an appropriate host cell with the expression vector. It can be prepared by transforming or transfecting, culturing this in an appropriate medium, expressing and purifying the VP1 protein.
- a nucleic acid for example, SEQ ID NO: 4 or the like
- Examples of host cells for expressing the VP1 protein include bacterial cells (eg, Escherichia coli B strain , E. coli Kl2 strain, Corynebacterium ammoniagenes , C. glutamicum , Serratia liquefaciens , Streptomyces lividans , Pseudomonas putida, etc.); molds (eg, Penicillium ) camembertii , Acremonium chrysogenum, etc.), animal cells, plant cells, baculovirus / insect cells or yeast cells (eg, Saccharomyces cerevisiae and Pichia pastoris ) can be used and expressed in these cells.
- bacterial cells eg, Escherichia coli B strain , E. coli Kl2 strain, Corynebacterium ammoniagenes , C. glutamicum , Serratia liquefaciens , Streptomyces lividans , Pse
- an expression vector for expressing the VP1 protein a vector suitable for various host cells can be used.
- expression vectors include, for example, pBR322, pBR325, pUC118, pET etc. (Escherichia coli host), pEGF-C, pEGF-N etc. (animal cell host), pVL1392, pVL1393 etc. (insect cell host, baculovirus vector), pG -1, Yep13 or pPICZ (yeast cell host) can be used.
- These expression vectors have a replication origin, a selection marker, and a promoter suitable for each vector, and may include an enhancer, a transcription assembly sequence (terminator), a ribosome binding site, a polyadenylation signal, and the like, if necessary. You may have. Furthermore, in order to facilitate purification of the expressed polypeptide, a base sequence for expressing by fusion of a FLAG tag, a His tag, an HA tag, a GST tag and the like may be inserted into the expression vector. Preparation of the expression vector can be carried out by a method known to those skilled in the art, and can also be carried out using a commercially available kit or the like as appropriate.
- the cells or cultured cells are collected by a known method, suspended in an appropriate buffer, and subjected to ultrasonic wave, lysozyme and / or lysozyme.
- a soluble extract is obtained by centrifugation or filtration.
- it is desirable to obtain the VP1 protein expressed in the culture supernatant by collecting the supernatant. From the obtained extract or culture supernatant, a desired protein can be obtained by appropriately combining known separation and purification methods.
- Known separation and purification methods include methods using solubility such as salting out and solvent precipitation, dialysis, ultrafiltration, gel filtration, methods using mainly differences in molecular weight such as SDS-PAGE, and ionization.
- a method using a charge difference such as exchange chromatography, a method using a specific affinity such as affinity chromatography (for example, when a polypeptide is expressed together with a GST tag, a resin in which glutathione is bound to a carrier is used.
- affinity chromatography for example, when a polypeptide is expressed together with a GST tag, a resin in which glutathione is bound to a carrier is used.
- affinity chromatography for example, when a polypeptide is expressed together with a GST tag, a resin in which glutathione is bound to a carrier is used.
- affinity chromatography for example, when a polypeptide is expressed together with a GST tag, a resin in which glutathione is bound to a carrier is used.
- the antibody produced in the first embodiment is not particularly limited, and may be, for example, a monoclonal antibody, a polyclonal antibody, a nanoantibody, or the like.
- an antigen can be used for an immunized animal (for example, but not limited to, rabbit, goat, sheep, chicken, guinea pig, mouse, rat or pig).
- an adjuvant mixture can be prepared.
- the antigen and / or adjuvant is injected multiple times into the immunized animal subcutaneously or intraperitoneally.
- Adjuvants include, but are not limited to, for example, complete Freund and monophosphoryl lipid A synthesis-trehalose dicorynomycolate (MPL-TMD).
- MPL-TMD monophosphoryl lipid A synthesis-trehalose dicorynomycolate
- serum containing an antibody against VP1 is prepared from the immunized animal, and the desired antibody can be purified by a conventional method (for example, a method using rProtein A-Sepharose).
- the term “monoclonal” refers to a property of an antibody obtained from a substantially homogeneous population of antibodies, and the antibody is produced by a specific method (eg, a hybridoma method). It does not mean to be done.
- a method for producing a monoclonal antibody include a hybridoma method (Kohler and Milstein, Nature 256 495 1975) or a recombinant method (US Pat. No. 4,816,567).
- the monoclonal antibody according to the present invention may be isolated from a phage antibody library (Clackson et al., Nature 352 624-628 1991; Marks et al., J. Mol. Biol. 222 581-597 1991).
- the preparation method includes, for example, the following four steps: (i) immunizing the VP1 protein of GII.17 HuNoV or a part thereof; Immunize animals, (ii) collect lymphocytes secreting (or potentially secreting) monoclonal antibodies, (iii) fuse lymphocytes with immortalized cells, (iv) secrete desired monoclonal antibodies Select cells.
- the immunized animal for example, mouse, rat, guinea pig, hamster and the like can be selected.
- lymphocytes obtained from the host animal are fused with an immortalized cell line using a fusion agent such as polyethylene glycol to establish hybridoma cells.
- a fusion agent such as polyethylene glycol
- the fused cells for example, rat or mouse myeloma cell lines are used.
- the cells are grown in a suitable medium containing unfused lymphocytes and one or more substrates that inhibit the growth or survival of the immortalized cell line.
- the usual technique uses parental cells that lack the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT).
- hypoxanthine, aminopterin and thymidine inhibit the growth of HGPRT-deficient cells and are added to a medium that allows hybridoma growth (HAT medium).
- HAT medium a medium that allows hybridoma growth
- a hybridoma producing a desired antibody is selected, and the desired monoclonal antibody can be obtained from a medium in which the selected hybridoma grows according to a conventional method.
- the hybridoma thus prepared can be cultured in vitro or in vivo in ascites of mice, rats, guinea pigs, hamsters, etc., and the target antibody can be prepared from the culture supernatant or ascites.
- a nanoantibody is a polypeptide comprising a variable domain of the heavy chain of an antibody (VHH).
- VHH antibody
- antibodies such as humans are composed of heavy chains and light chains.
- Camelid animals such as llamas, alpacas and camels produce single-chain antibodies consisting only of heavy chains (heavy chain antibodies).
- a heavy chain antibody can recognize a target antigen and bind to the antigen, similarly to a normal heavy and light chain antibody.
- the variable region of a heavy chain antibody is the smallest unit that has binding affinity for an antigen, and this variable region fragment is called a "nanoantibody.”
- Nanoantibodies have high heat resistance, digestion resistance, and room temperature stability, and can be easily prepared in large quantities by genetic engineering techniques. Nanoantibodies can be prepared, for example, as follows.
- a camelid animal is immunized with an antigen, the presence or absence of the target antibody is detected from the collected serum, and cDNA is prepared from RNA derived from peripheral blood lymphocytes of the immunized animal in which the desired antibody titer has been detected.
- a VHH-encoding DNA fragment is amplified from the obtained cDNA and inserted into a phagemid to prepare a VHH phagemid library.
- a desired nanoantibody can be prepared from the prepared VHH phagemid library through several screenings.
- a second embodiment of the present invention relates to an antibody that binds to the VP1 protein of GII.17 HuNoV, wherein the antibody inhibits infection of multiple different genotypes of HuNoV into intestinal epithelial cells (hereinafter referred to as “the antibody of the present invention Or a functional fragment thereof.
- the antibody of the present invention is not particularly limited, and may be, for example, a monoclonal antibody, a polyclonal antibody, or a nanoantibody.
- the antibody of the present invention may be a recombinant antibody.
- the recombinant antibody is not particularly limited, and includes, for example, chimeric antibodies (for example, humanized antibodies and human antibodies).
- a chimeric antibody is an antibody in which a variable region and a constant region derived from different animal species are linked, for example, an antibody in which the variable region of a mouse-derived antibody is linked to a human-derived constant region.
- Such linked antibodies can easily be constructed by genetic recombination techniques well known to those skilled in the art.
- the genotype of HuNoV that the antibody of the present invention inhibits infection is preferably GII.4 and GII.17.
- a functional fragment of the antibody of the present invention is a partial region of the antibody of the present invention, which means an antibody fragment that binds to HuNoV VPL and inhibits its infection or proliferation in intestinal epithelial cells, for example, Fab, Fab ', F (ab') 2, Fv (variable fragment of antibody), single chain antibody (heavy chain, light chain, heavy chain variable region, light chain variable region, nano antibody, etc.), scFv (single chain) Fv), diabody (scFv dimer), dsFv (disulfide-stabilized ⁇ Fv), and peptides containing at least a part of the CDR of the antibody of the present invention.
- Fab is an antibody fragment having antigen-binding activity in which about half of the N-terminal side of the heavy chain and the entire light chain are bound by disulfide bonds, among fragments obtained by treating an antibody molecule with the protease, papain.
- Fab is prepared by treating the antibody molecule with papain to obtain a fragment, for example, constructing an appropriate expression vector into which DNA encoding Fab is inserted, and inserting it into an appropriate host cell (for example, CHO cell or the like). After introduction into mammalian cells, yeast cells, insect cells, and the like), and then expressing Fab in the cells.
- F (ab ') 2 is an antibody fragment having an antigen-binding activity, which is a little larger than a fragment obtained by treating an antibody molecule with the protease pepsin, wherein the Fab is bound via a disulfide bond in the hinge region. It is.
- F (ab ') 2 can be prepared by treating the antibody molecule with pepsin to obtain a fragment, or by linking the Fab to a thioether bond or a disulfide bond. can do.
- Fab' is an antibody fragment having antigen-binding activity, which is obtained by cleaving a disulfide bond in the hinge region of F (ab ') 2.
- scFv is a VH-linker-VL or VL-linker-VH polypeptide in which one heavy chain variable region (VH) and one light chain variable region (VL) are linked using an appropriate peptide linker. And an antibody fragment having an antigen-binding activity.
- the scFv can be prepared by obtaining cDNAs encoding the heavy chain variable region and the light chain variable region of the antibody, and using a genetic engineering technique.
- Diabody is an antibody fragment obtained by dimerizing scFv and has a bivalent antigen-binding activity.
- the divalent antigen-binding activities may be the same antigen-binding activity or one may be a different antigen-binding activity.
- the diabody obtains cDNAs encoding the heavy chain variable region and light chain variable region of the antibody, constructs a cDNA expressing the scFv in which the heavy chain variable region and the light chain variable region are linked by a peptide linker, and performs genetic engineering. It can be produced by a technique.
- DsFv refers to a polypeptide in which one amino acid residue in each of the heavy chain variable region and the light chain variable region has been substituted with a cysteine residue, which is linked via a disulfide bond between the cysteine residues.
- the amino acid residue to be substituted for the cysteine residue can be selected based on the prediction of the three-dimensional structure of the antibody.
- dsFv can be prepared by obtaining cDNAs encoding the heavy chain variable region and the light chain variable region of an antibody, constructing a DNA encoding the dsFv, and performing genetic engineering techniques.
- the peptide containing the CDR is configured to include at least one region or more of the heavy chain or light chain CDRs (CDR1 to 3). Peptides containing multiple CDRs can be linked directly or via a suitable peptide linker.
- a DNA encoding the heavy chain or light chain CDR of the antibody is constructed and inserted into an expression vector.
- the type of the vector is not particularly limited, and may be appropriately selected depending on the type of the host cell to be subsequently introduced. These can be produced by introducing them into an appropriate host cell (eg, a mammalian cell such as a CHO cell, a yeast cell, an insect cell, etc.) in order to express them as an antibody.
- an appropriate host cell eg, a mammalian cell such as a CHO cell, a yeast cell, an insect cell, etc.
- the peptide containing CDR can also be produced by a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the
- the third embodiment of the present invention is a medicine containing the antibody of the present invention or a functional fragment thereof (hereinafter, also referred to as “the medicine of the present invention”).
- the medicament of the present invention has a pharmacological effect as a prophylactic and / or therapeutic agent for infections caused by HuNoV.
- the medicament of the present invention may be in a form in which the antibody of the present invention as an active ingredient or the functional fragment thereof itself is administered, but generally, in addition to the antibody of the present invention as an active ingredient or the functional fragment thereof, Alternatively, it is desirable to administer in the form of a pharmaceutical composition containing two or more pharmaceutical additives (hereinafter also referred to as “the pharmaceutical composition of the present invention”). Further, the pharmaceutical composition according to the embodiment of the present invention may further contain other known drugs.
- the medicament or the pharmaceutical composition according to the embodiment of the present invention is not particularly limited, and may be in the form of a tablet, capsule, granule, powder, syrup, suspension, suppository, ointment, cream, gel. Preparations, patches, inhalants or injections. These preparations are prepared according to a conventional method. In the case of liquid preparations, they may be dissolved or suspended in water or another suitable solvent at the time of use. Tablets and granules may be coated by a known method. In the case of an injection, the antibody of the present invention or a functional fragment thereof is prepared by dissolving the same in water, but may be dissolved in a physiological saline solution or a glucose solution if necessary, An agent may be added.
- Formulations for oral or parenteral administration are provided in any formulation form.
- Formulation forms include, for example, oral administration agents in the form of granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions or solutions, intravenous administration, intramuscular It can be prepared in the form of injections, drops, transdermal absorbents, transmucosal absorbents, nasal drops, inhalants or suppositories for administration or subcutaneous administration. Injections, drops, and the like can be prepared as a powdery dosage form such as a lyophilized form, and dissolved in an appropriate aqueous medium such as physiological saline before use.
- the type of the pharmaceutical additive used in the production of the medicament or the pharmaceutical composition according to the embodiment of the present invention, the ratio of the pharmaceutical additive to the active ingredient, or the method of producing the medicament or the pharmaceutical composition depends on the form. Thus, a person skilled in the art can select as appropriate. Inorganic or organic substances, or solid or liquid substances can be used as pharmaceutical additives. Generally, for example, 0.1% to 99.9% by weight, 1% to 1% by weight based on the weight of the active ingredient. 95.0% by weight, or between 1% and 90.0% by weight.
- lactose glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium aluminate metasilicate, synthetic aluminum silicate, sodium carboxymethylcellulose, hydroxypropyl starch, carboxymethylcellulose calcium as examples of pharmaceutical additives , Ion exchange resins, methylcellulose, gelatin, gum arabic, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, titanium oxide, sorbitan fatty acid ester, Sodium lauryl sulfate, glycerin, fatty acid glycerin ester, purified lanolin, glycerogelatin, polysodium Bate, macrogol, vegetable oils, waxes, liquid paraffin, white petrolatum, fluorocarbons, nonionic surfactants
- the active ingredient and excipient components for example, lactose, starch, microcrystalline cellulose, calcium lactate or silicic acid anhydride and the like, or a powder, or A binder such as sucrose, hydroxypropylcellulose or polyvinylpyrrolidone, a disintegrant such as carboxymethylcellulose or calcium carboxymethylcellulose are added, and the mixture is granulated by wet or dry granulation to give granules.
- these powders and granules may be compressed as they are or by adding a lubricant such as magnesium stearate or talc.
- granules or tablets are coated with an enteric base such as hydroxypropylmethylcellulose phthalate or methacrylic acid-methyl methacrylate polymer to form an enteric coated preparation, or coated with ethyl cellulose, carnauba wax or hardened oil to obtain a sustained release preparation. You can also.
- an enteric base such as hydroxypropylmethylcellulose phthalate or methacrylic acid-methyl methacrylate polymer
- enteric coated preparation or coated with ethyl cellulose, carnauba wax or hardened oil to obtain a sustained release preparation.
- To produce capsules powders or granules are filled in hard capsules, or the active ingredient is used as it is, or is dissolved in glycerin, polyethylene glycol, sesame oil or olive oil, and then coated with gelatin to form soft capsules. be able to.
- the active ingredient may be used as necessary, such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, a pH adjuster such as sodium monohydrogen phosphate or sodium dihydrogen phosphate, sodium chloride or glucose, etc. Dissolve in distilled water for injection together with an isotonic agent, and aseptically filter and fill into ampoules, or add mannitol, dextrin, cyclodextrin or gelatin, and freeze-dry in vacuo to obtain a working-soluble injection. Is also good.
- reticin, polysorbate 80, polyoxyethylene hydrogenated castor oil or the like may be added to the active ingredient and emulsified in water to prepare an injection emulsion.
- the active ingredient is dissolved by humidification together with a suppository base such as cocoa butter, fatty acid tri-, di- and monoglycerides or polyethylene glycol, and then poured into a mold and cooled, or the active ingredient is cooled. After dissolving in polyethylene glycol or soybean oil or the like, it may be coated with a gelatin film.
- a suppository base such as cocoa butter, fatty acid tri-, di- and monoglycerides or polyethylene glycol
- the dose and the number of times of administration of the medicament or the pharmaceutical composition according to the embodiment of the present invention are not particularly limited, and the purpose of preventing and / or treating the deterioration and progression of the target disease, the type of the disease, the weight and age of the patient, and the like Can be appropriately selected by the judgment of the doctor or pharmacist according to the conditions of In general, the daily dose for oral administration in adults is about 0.01 to 1,000 mg (weight of active ingredient), and it can be administered once or several times a day or every few days . When used as an injection, it is desirable to continuously or intermittently administer a daily dose of 0.001 to 100 mg (weight of the active ingredient) to an adult.
- the medicament or the pharmaceutical composition according to the embodiment of the present invention is prepared as a sustained-release preparation such as an implant and a delivery system encapsulated in microcapsules using a carrier capable of preventing immediate removal from the body.
- a carrier capable of preventing immediate removal from the body.
- biodegradable and biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acids can be used. Such materials can be easily prepared by those skilled in the art.
- a suspension of liposomes can be used as a pharmaceutically acceptable carrier.
- Liposomes are prepared through a filter of appropriate pore size to a size suitable for use as a lipid composition comprising, but not limited to, phosphatidylcholine, cholesterol and PEG-derived phosphatidylethanol (PEG-PE). Can be purified by
- the medicament or the pharmaceutical composition according to the embodiment of the present invention may be provided in the form of a kit together with instructions such as an administration method.
- the medicament or the pharmaceutical composition contained in the kit is manufactured from a material that maintains the activity of the active ingredient effectively for a long period of time, does not cause the agent or the like to adsorb to the inside of the container, and does not alter the components. Supplied by container.
- a sealed glass ampoule may include a buffer or the like encapsulated in the presence of a neutral, non-reactive gas such as nitrogen gas.
- the kit may be accompanied by instructions for use. Instructions for use of the kit may be printed on paper or the like, or may be stored and supplied on an electromagnetically readable medium such as a CD-ROM or DVD-ROM.
- a fourth embodiment of the present invention provides a vaccine for suppressing infection of a plurality of different genotypes of HuNoV, which contains the full length or a part of the VP1 protein of GII.17 HuNoV as an antigen (hereinafter referred to as “the vaccine of the present invention”). ").
- the vaccine of the present invention may comprise one or more adjuvants, such as complete Freund's or incomplete Freund's adjuvant, cholera toxin, heat-labile Escherichia coli toxin, aluminum hydroxide, potassium alum, saponin or a derivative thereof, muramyl dipeptide, mineral oil or Vegetable oils, novasomes or non-ionic block copolymers, DEAE dextran and the like can be included.
- adjuvants such as complete Freund's or incomplete Freund's adjuvant, cholera toxin, heat-labile Escherichia coli toxin, aluminum hydroxide, potassium alum, saponin or a derivative thereof
- a pharmaceutically acceptable carrier must be a compound that does not adversely affect the health of the animal being vaccinated.
- a pharmaceutically acceptable carrier is, for example, sterile water or a buffer.
- the vaccine of the present invention can be administered by a conventional active immunization method, and may be administered by injection, orally, or by a transmucosal method such as nasal.
- the vaccine preparation of the present invention can be administered in a single dose by a method suitable for the dosage form in an amount effective for preventing or treating HuNoV infection (an amount sufficient to induce immunity in animals against HuNoV challenge). Or it can be administered multiple times.
- the vaccine can be administered intradermally, subcutaneously, intramuscularly, intraperitoneally, intravenously, orally, or mucosally, such as intranasally or sublingually.
- the vaccine preparation of the present invention can be used by mixing with other antigen components.
- the dose and frequency of administration of the vaccine preparation may vary depending on the administration subject, but protective immunity can be induced by administering the vaccine containing several tens of ⁇ g of the antigen once every several weeks, once every several weeks.
- a fifth embodiment of the present invention comprises administering to a patient a medicament or pharmaceutical composition of the present invention or a vaccine of the present invention, wherein a plurality of different genotypes of HuNoV (eg, GII.4 and GII.17).
- ⁇ treatment '' refers to preventing or alleviating the progress and worsening of the disease state in a patient already infected with HuNoV, and thereby preventing or alleviating the progress and worsening of HuNoV infection. Is the action to be taken.
- ⁇ prevention '' means, for a patient who may be infected with HuNoV, preventing the infection in advance, and thereby a treatment aimed at preventing the onset of HuNoV infection in advance. .
- VLP VLP and polyclonal antibody against VLP
- the virus was roughly purified from stool containing HuNoV donated by Osaka National Institute of Health and Safety, and a virus genome was prepared therefrom. Primers were set outside the VP1 ORFs of GII.4, GII.3 and GII.17 on the prepared genome, each ORF region was amplified by PCR, and the nucleotide sequence of the amplified product was determined. The ORF of each VP1 was cloned into pFastBac Dual Expression Vector (Invitrogen).
- the amino acid sequence of GII.4 VP1 and the nucleic acid sequence encoding the same are shown in SEQ ID NOS: 1 and 2, respectively, and the amino acid sequence of GII.17 VP1 and the nucleic acid sequence encoding the same are shown in SEQ ID NOs: 3 and 4, respectively.
- the amino acid sequence of GII.3 VP1 and the nucleic acid sequence encoding it are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. After confirming that the sequence was correct, each construct was used for producing a recombinant baculovirus of the Bac-to-Bac expression system (Invitrogen).
- High Five cells (Invitrogen) were infected with each recombinant baculovirus at a MOI (multiplicity of infection) of 7 pfu (plaque-forming units) / cell.
- MOI multiple of infection
- the culture supernatant was collected and centrifuged at 20,000 g for 1 hour.
- the obtained supernatant was ultracentrifuged at 100,000 g for 2 hours, and the precipitated VLP was suspended in PBS.
- the concentrated VLPs were layered on a 10% -60% sucrose density gradient and purified by ultracentrifugation at 100,000 g for 1 hour.
- VLPs passed through the sucrose density gradient were dialyzed three times against 2 L of PBS to remove sucrose in the sample.
- VLP was concentrated with AmiconUltra 30-kDa centrifugal filter (Millipore).
- VLP GII.4, GII.3 or GII.17
- complete Freund's adjuvant 100-200 ⁇ g
- each rabbit received a booster injection with 100-200 ⁇ g of VLP mixed with incomplete Freund's adjuvant.
- rabbits were bled for serum preparation.
- the IgG fraction of the serum was purified by rProtein A-Sepharrose Fast flow (GE Healthcare) and then dialyzed 3 times against 2 L of PBS.
- the obtained cell suspension was added to a 5-fold volume of 10% calf serum / basic medium [Advanced DMEM / F12 (Gibco) in 10 mM HEPES (pH 7.3, Gibco), 2 mM Glutamax (Gibco) and 100 units / mL Penicillin plus 100 ⁇ g / mL streptmycin (Gibco) was added], and the mixture was centrifuged at 440 g for 5 minutes to collect the cells.
- the collected intestinal epithelial cells were cultured on ice on a 20% organoid culture medium supplemented with 10 ⁇ M Y-27632 [a medium obtained by adding the following to a basic medium.
- an organoid culture medium (+10 ⁇ M Y-27632) was added to each well.
- the average passage ratio was 1:16 or 3 ⁇ 10 4 / well.
- the medium was replaced with a fresh organoid medium every 2-3 days. Passaging was performed every 5-7 days.
- intestinal epithelial cells that had been removed from the wells and suspended in 100 ⁇ L of an organoid culture medium (+10 ⁇ M Y-27632) in a 2.5% Matrigel-coated 96-well plate or Transwells (Corning3470) were used for 2 ⁇ 10 5 Seeded at a cell density of 4 / well.
- an organoid culture medium (+10 ⁇ M Y-27632) in a 2.5% Matrigel-coated 96-well plate or Transwells (Corning3470) were used for 2 ⁇ 10 5 Seeded at a cell density of 4 / well.
- 600 ⁇ L of an organoid culture medium was added to the lower well. After culturing in a 5% CO 2 incubator at 37 ° C. for 2 days, the medium was used as a differentiation medium [a medium obtained by adding the following to a basic medium.
- RN CM 12.5% RN CM (Takahashi et al., Stem Cell Reports 10: 314-328 2018), 1 ⁇ B-27, 50 ng / mL mouse EGF and 500 nM A83-01].
- the medium was replaced with a differentiation medium with or without 0.03% porcine bile (Sigma). Thereafter, the cells cultured for 2 days were used for HuNoV infection.
- the cells were washed twice with 150 ⁇ L of the basal medium.
- a differentiation medium containing or not containing 0.03% bile was added to 100 ⁇ L cells, and pipetted twice, and then collected as a control sample.
- 100 ⁇ L of differentiation medium with or without 0.03% bile was added to each well and then cultured in 5% CO 2 for 72 hours.
- GII.4 Antibody prepared using VLP as an antigen Compared with VLP used as an antigen, VP1 of the virus strain (17-231) contained a single amino acid mutation (D235E) in the P1 domain.
- Incubation of .4 HuNoV with anti-GII.4 VLP antibody completely inhibited its replication in intestinal epithelial cells (FIG. 1A).
- FIG. 1A Incubation of .4 HuNoV with anti-GII.4 VLP antibody completely inhibited its replication in intestinal epithelial cells (FIG. 1A).
- FIG. 1A intestinal epithelial cells
- the anti-GII.4 VLP polyclonal antibody prepared here was unable to inhibit the replication of GII.3, GII.6 and GII.17 HuNoV (FIG. 1B). This result suggests that GII.4 VLP cannot be used as an antigen to induce neutralizing antibodies that inhibit the replication of other genotypes of HuNoV.
- Antibody prepared using GII.17 VLP as an antigen Pretreatment of GII.17 HuNoV with an anti-GII.17 VLP antibody inhibited the replication of GII.17 HuNoV in intestinal epithelial cells (FIG. 3A). Next, when the effect of the anti-GII.17 VLP antibody on the replication of HuNoV of a genotype other than GII.17 was examined, the anti-GII.17 VLP antibody also inhibited the replication of GII.4 HuNoV (FIG. 3B).
- GII.17 VLP is highly likely to inhibit the infection of HuNoV of other genotypes classified as GII and has the ability as a multivalent vaccine antigen.
- the present invention provides an antigen suitable for the purpose of preparing an antibody that inhibits HuNoV infection of a plurality of different genotypes, and the antibody. Therefore, the present invention is expected to be used in the medical field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention a pour objet de fournir un antigène permettant de générer un anticorps pour inhiber l'infection par de multiples types de HuNov, une utilisation associée, et un anticorps pour inhiber l'infection par de multiples types de HuNov. Plus particulièrement, la présente invention concerne : un procédé de production d'un anticorps pour inhiber l'infection de cellules épithéliales intestinales par différents génotypes de norovirus humain (HuNoV), comprenant l'immunisation à l'aide d'une protéine VP1 de GII.17 HuNoV pleine longueur ou d'une partie de celle-ci en tant qu'antigène ; et un anticorps pour inhiber l'infection de cellules épithéliales intestinales par une pluralité de génotypes différents de HuNoV.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020537449A JPWO2020036135A1 (ja) | 2018-08-13 | 2019-08-09 | ヒトノロウイルス様粒子およびその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-152166 | 2018-08-13 | ||
JP2018152166 | 2018-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020036135A1 true WO2020036135A1 (fr) | 2020-02-20 |
Family
ID=69524800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/031571 WO2020036135A1 (fr) | 2018-08-13 | 2019-08-09 | Particule de type norovirus humain et utilisation associée |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2020036135A1 (fr) |
WO (1) | WO2020036135A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022244860A1 (fr) * | 2021-05-20 | 2022-11-24 | デンカ株式会社 | Anticorps anti-norovirus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
US20160102136A1 (en) * | 2013-05-09 | 2016-04-14 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
WO2018181866A1 (fr) * | 2017-03-31 | 2018-10-04 | 国立大学法人東京大学 | Anticorps de norovirus |
JP2019149996A (ja) * | 2018-03-06 | 2019-09-12 | 株式会社イーダブルニュートリション・ジャパン | 貝類のノロウイルス不活化方法 |
-
2019
- 2019-08-09 JP JP2020537449A patent/JPWO2020036135A1/ja not_active Withdrawn
- 2019-08-09 WO PCT/JP2019/031571 patent/WO2020036135A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
US20160102136A1 (en) * | 2013-05-09 | 2016-04-14 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
WO2018181866A1 (fr) * | 2017-03-31 | 2018-10-04 | 国立大学法人東京大学 | Anticorps de norovirus |
JP2019149996A (ja) * | 2018-03-06 | 2019-09-12 | 株式会社イーダブルニュートリション・ジャパン | 貝類のノロウイルス不活化方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022244860A1 (fr) * | 2021-05-20 | 2022-11-24 | デンカ株式会社 | Anticorps anti-norovirus |
Also Published As
Publication number | Publication date |
---|---|
JPWO2020036135A1 (ja) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022262142A1 (fr) | Vaccin à base de protéine rbd tripolymère de sars-cov-2 recombinante capable de générer une activité de neutralisation croisée à large spectre, son procédé de préparation et son utilisation | |
do Carmo Caldeira et al. | Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7 | |
CN100506999C (zh) | Hpv31l1在酵母中的优化表达 | |
US8512703B2 (en) | Idiotypic vaccine | |
US20230117167A1 (en) | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF | |
TWI688652B (zh) | 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造 | |
Harmsen et al. | Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease | |
RU2764740C1 (ru) | Биспецифическое антитело против вируса бешенства и его применение | |
JP6942309B2 (ja) | フラビウイルスウイルス様粒子 | |
JP2008532559A (ja) | ウイルス感染の治療及び予防又は治療及び予防の改善 | |
US20210401983A1 (en) | Arthrogenic alphavirus vaccine | |
WO2023138334A1 (fr) | Vaccin à nouvelle protéine de coronavirus recombinante, son procédé de préparation et son application | |
Saied et al. | Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: a review article | |
WO2016173559A1 (fr) | Préparation et utilisation de l'anticorps monoclonal murin contre le norovirus gi.1 | |
US11530254B2 (en) | Norovirus antibody | |
KR20220009960A (ko) | 재조합 고전적 돼지 열병 바이러스 | |
WO2020036135A1 (fr) | Particule de type norovirus humain et utilisation associée | |
Xiang et al. | Neutralizing monoclonal antibodies against highly pathogenic coronaviruses | |
BRPI0924072B1 (pt) | Anticorpos antivírus do herpes simples, seu método de produção, uso dos mesmos, ácido nucleico, vetor, célula hospedeira, método de produção da referida célula, bem como composição farmacêutica | |
Almendárez-Rodriguez et al. | Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus | |
WO2023138333A1 (fr) | Vaccin recombinant à base de protéine sars-cov-2, son procédé de préparation et son utilisation | |
KR20150135231A (ko) | 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편 | |
WO2023182244A1 (fr) | Anticorps spécifique au norovirus humain gii.2 | |
WO2024085207A1 (fr) | Antisérum équin contre le bêtacoronavirus | |
US20240067706A1 (en) | Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19850176 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020537449 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19850176 Country of ref document: EP Kind code of ref document: A1 |